Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech
Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018 Capital Markets and Public M&A

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge has advised Nordion Energi AB in connection with the acquisition of shares in Kalmar Energi

 Nordion Energi acquires E.ON Sverige AB’s entire stake in Kalmar Energi and in connection with the completion of such, divest Kalmar Energi’s electricity retail business to Siljansvik AB (publ).
May 29, 2026

Vinge advises Latour on the sale of shares in ASSA ABLOY and Securitas, amounting to SEK 2.5 billion in each company

 Vinge has advised Investmentaktiebolaget Latour (publ) in connection with the sale of parts of its shareholdings in ASSA ABLOY and Securitas for a total value of SEK 5 billion.
May 27, 2026

Vinge advises Hybridge Group on the acquisition of NESC

 Hybridge Group and the consultancy firm NESC are merging. Through the merger, Hybridge Group is strengthening its offering in the field of prefabricated structural solutions.
May 27, 2026